Following a traumatic brain injury, patients frequently experience enduring personality changes such as irritability, depression, and mood swings.

Increased digital screen time is associated with a higher likelihood of experiencing migraines and headaches in adult and pediatric patients.

Phase 3 LUNA trial results show atogepant significantly reduces menstrual migraine days in adult women, meeting all primary and secondary endpoints.

The FDA granted Breakthrough Therapy designation to certolizumab pegol for preventing placenta-mediated adverse pregnancy outcomes in patients with antiphospholipid syndrome.

Measles cases continue rising in Pennsylvania, including an unvaccinated woman whose death is likely related to measles.

Disorders of the voice may be an early indicator of elevated risk for incident cognitive decline, with strong links to dementia.

A virtual reality toolkit may be a feasible intervention for patients that experience anxiety or claustrophobia during PET or CT imaging.

Increased use of SAMA or SAMA and SABA is associated with increased risk for mortality and cardiovascular events among patients with asthma or COPD.

Restricting sugar intake in utero and during the first years of life is linked to a reduced risk for dementia and Alzheimer disease in adulthood.

The FDA granted Priority Review to satralizumab for MOGAD, a rare CNS demyelinating disease, backed by phase 3 METEOROID trial data showing a 68% risk reduction.

A novel speech-based model successfully distinguishes between nonfluent, logopenic, and semantic variants of primary progressive aphasia.

Patients with newly diagnosed MS may see greater effects on acute inflammatory outcomes with BCDTs and high-efficacy therapies.